MOR vs. MLTX, MRUS, ACAD, SMMT, PTCT, ARWR, CORT, INDV, RYTM, and JANX
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include MoonLake Immunotherapeutics (MLTX), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Summit Therapeutics (SMMT), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Corcept Therapeutics (CORT), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
MorphoSys (NASDAQ:MOR) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than MorphoSys. MarketBeat recorded 14 mentions for MoonLake Immunotherapeutics and 2 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.77 beat MoonLake Immunotherapeutics' score of 0.59 indicating that MorphoSys is being referred to more favorably in the media.
MorphoSys has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
MorphoSys presently has a consensus price target of $11.78, indicating a potential downside of 34.08%. MoonLake Immunotherapeutics has a consensus price target of $74.46, indicating a potential upside of 77.42%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than MorphoSys.
MoonLake Immunotherapeutics received 22 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 77.05% of users gave MoonLake Immunotherapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than MorphoSys. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
18.4% of MorphoSys shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 15.3% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. MoonLake Immunotherapeutics' return on equity of -9.22% beat MorphoSys' return on equity.
Summary
MoonLake Immunotherapeutics beats MorphoSys on 14 of the 17 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
